Simple breathing device shows promise for lung disease fatigue
NCT ID NCT06991153
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested whether using a Lung Boost breathing trainer could improve lung function and reduce fatigue in people with interstitial lung disease. Forty women with the condition used the device three times a week for eight weeks. Researchers measured their lung capacity, oxygen levels, and fatigue before and after the training.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Lung Boost Respiratory Trainer (MD800) - a breathing exercise device
- What this could lead to
- If it works, this breathing exercise could help people with interstitial lung disease breathe easier and feel less tired.
- What could go wrong
- This is a small, completed trial with only 40 women, so results may not apply to everyone. The device is an exercise tool, not a treatment for the disease itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
40 people
The number who actually took part.
- Started
-
May 2025
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 to 55 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Forty female patients have Interstitial lung disease . 2. All patients diagnosed as ILD on clinical and radiological basis. 3. Age will range between 45 to 55 years old . 4. All patients will be with mild hypoxemia range from 90 to 92 oxygen saturation 5. They have Interstitial lung disease for at least 3 years ago. 6. Stable in medical and hemodynamic state Exclusion Criteria: 1. Cardiovascular (as acute heart failure, unstable angina or recent myocardial infarction) 2. Patients with other significant respiratory disorders such as acute infections, pulmonary tuberculosis, chronic obstructive pulmonary disease, asthma, bronchiectasis, lung carcinoma, and pneumothorax. 3. cognitive impairments, history of cerebrovascular accident, active cancer will be excluded. 4. Hepatitis, cirrhosis. 5. Current treatment for cancer or active infection 6. Orthopedic problem.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Interstitial lung disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faculty of physical therapy, Cairo University
Giza, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Device-Preserved donor lungs boost transplant success?
- Patients and families build a living database of pulmonary fibrosis
- Can better training get doctors to talk about what matters most to dying veterans?
- Inhaled xenon gas could reveal hidden lung vessel disease without catheter
- Radioactive tracer aims to light up hidden lung scarring
- Inhaled drug aims to ease dangerous lung blood pressure in scarred lungs